FDA Warns Public About Vascular Device After 3 Deaths

Why It Matters

The alert underscores a critical patient‑safety risk in endovascular aortic repair and could reshape procurement decisions for hospitals and vascular surgeons nationwide.

Key Takeaways

• FDA issued early alert for Relay Pro thoracic stent grafts.
• Three patient deaths linked to unclasping failure as of April 23.
• Issue affects non‑bare stents sized 32 mm and larger.
• Terumo Aortic recommends using alternative devices pending mitigation.
• Open‑surgery conversion may be required if bailout techniques fail.

Pulse Analysis

The FDA’s early‑alert on the Relay Pro Thoracic Stent Graft highlights how device‑specific failures can quickly become public‑health concerns. The stent, designed for minimally invasive repair of the thoracic aorta, has a known failure mode where the graft does not release from its delivery catheter. When this occurs, the procedure can stall, forcing surgeons to convert to open repair—a step that carries higher morbidity and, in the reported cases, resulted in fatal outcomes. The agency’s rapid communication aims to protect patients while the manufacturer investigates root causes.

Hospitals and vascular teams are now weighing risk mitigation strategies. Terumo Aortic’s recommendation to switch to alternative grafts reflects a cautious approach, especially for high‑risk patients. Clinicians must review the device’s instructions for use, rehearse bailout techniques, and be prepared for immediate surgical conversion if the clasp fails. The alert also prompts procurement departments to reassess inventory, potentially accelerating contracts with competing manufacturers that offer proven release mechanisms. For surgeons, the situation reinforces the importance of device familiarity and contingency planning in endovascular procedures.

From a market perspective, the early‑alert could pressure Terumo Aortic’s share in the thoracic stent‑graft segment. If the investigation leads to a formal recall, the company may face costly redesigns, litigation, and a dip in sales while competitors capitalize on the gap. The episode also illustrates the FDA’s proactive stance on device safety, encouraging manufacturers to embed robust post‑market surveillance and rapid response protocols. Stakeholders across the cardiovascular device ecosystem will watch closely for further updates, as the outcome may set precedents for handling similar device‑related adverse events.